OTCPK:INVS

Stock Analysis Report

Executive Summary

InnoVision Labs, Inc., a visual neuroscience software technology company, develops and commercializes consumer-oriented software applications.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has InnoVision Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

INVS

1.8%

US Healthcare Services

2.3%

US Market


1 Year Return

n/a

INVS

13.0%

US Healthcare Services

5.6%

US Market

Return vs Industry: Insufficient data to determine how INVS performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how INVS performed against the US Market.


Shareholder returns

INVSIndustryMarket
7 Day0%1.8%2.3%
30 Day-4.3%-1.5%-1.0%
90 Day-56.0%-6.2%-0.7%
1 Yearn/a13.2%13.0%7.9%5.6%
3 Year-73.2%-73.2%56.8%56.2%45.6%36.3%
5 Year-98.8%-98.8%52.1%51.0%65.8%47.6%

Price Volatility Vs. Market

How volatile is InnoVision Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is InnoVision Labs undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether InnoVision Labs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as InnoVision Labs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of INVS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through InnoVision Labs regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is InnoVision Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InnoVision Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of INVS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access InnoVision Labs's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has InnoVision Labs performed over the past 5 years?

16.7%

Historical Healthcare annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if INVS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare INVS's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if INVS's earnings growth over the past year exceeded the Healthcare Services industry average.


Return on Equity

High ROE: INVS has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: Insufficient data to calculate INVS's Return on Assets to determine if it is higher than the Healthcare Services industry average last year.


Return on Capital Employed

ROCE Improving: Insufficient data to calculate INVS's Return on Capital Employed to determine if it has improved over the past 3 years.


Next Steps

Financial Health

How is InnoVision Labs's financial position?


In this section we usually analyse InnoVision Labs's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. InnoVision Labs has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of INVS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when InnoVision Labs's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is InnoVision Labs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate INVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate INVS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if INVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INVS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of InnoVision Labs's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average management tenure


CEO

InnoVision Labs has no CEO, or we have no data on them.


Management Age and Tenure

6.3yrs

Average Tenure

66yo

Average Age

Experienced Management: INVS's management team is seasoned and experienced (6.3 years average tenure).


Board Age and Tenure

6.3yrs

Average Tenure

51yo

Average Age

Experienced Board: INVS's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Uri Polat (66yo)

    Chief Scientific Officer and Director

    • Tenure: 6.3yrs
    • Compensation: US$251.66k
  • Steve Schaeffer (69yo)

    Chief Financial Officer

    • Tenure: 6.3yrs
  • Ram Shaffir (49yo)

    Chief Technology Officer and Director

    • Tenure: 6.3yrs
    • Compensation: US$181.15k

Board Members

  • Shai Novik (53yo)

    Independent Chairman

    • Tenure: 6.3yrs
    • Compensation: US$75.00k
  • Yuval Bar-Gil (51yo)

    Independent Director

    • Tenure: 4.8yrs
  • Uri Polat (66yo)

    Chief Scientific Officer and Director

    • Tenure: 6.3yrs
    • Compensation: US$251.66k
  • Ram Shaffir (49yo)

    Chief Technology Officer and Director

    • Tenure: 6.3yrs
    • Compensation: US$181.15k
  • Nimrod Madar (46yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$316.34k

Company Information

InnoVision Labs, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InnoVision Labs, Inc.
  • Ticker: INVS
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$2.101m
  • Shares outstanding: 19.10m
  • Website: https://null

Number of Employees


Location

  • InnoVision Labs, Inc.
  • 5 Jabotinski Street
  • POB 12
  • Ramat Gan
  • 5252006
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INVSOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDJul 2013

Biography

InnoVision Labs, Inc., a visual neuroscience software technology company, develops and commercializes consumer-oriented software applications. The company offers GlassesOff, a software visual cortex exerci ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:13
End of Day Share Price2019/09/23 00:00
Earnings2016/09/30
Annual Earnings2015/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.